sorafenib has been researched along with Graft vs Host Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dai, M; Fan, Z; Huang, F; Huang, J; Liang, X; Liu, H; Liu, Q; Nie, D; Shi, P; Sun, J; Sun, Q; Wang, Z; Xu, J; Xu, N; Xuan, L; Yu, G; Zhang, X; Zhang, Y | 1 |
| Chen, Y; Deng, L; Fan, Z; Huang, F; Huang, X; Li, X; Liang, X; Liu, H; Liu, Q; Luo, X; Shi, P; Sun, J; Tu, S; Wang, Y; Xu, N; Xu, X; Xu, Y; Xuan, L | 1 |
| Chen, Y; Chi, P; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shao, R; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yang, K; Zhang, Y | 1 |
| Chen, Y; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yu, C; Zhou, X | 1 |
| Assanto, GM; Barberi, W; Brescini, M; Bruzzese, A; Carmini, D; De Propris, MS; Diverio, D; Galassi, G; Iori, AP; La Rocca, U; Quattrocchi, L; Trisolini, SM | 1 |
| Fuji, S | 1 |
| Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A | 1 |
| Andrieux, G; Antin, JH; Apostolova, P; Arnold, R; Ayuk, F; Bar, M; Baumgartner, F; Becher, B; Beelen, D; Bertz, H; Bethge, W; Bettinger, D; Blazar, BR; Bonini, C; Börries, M; Braun, L; Brummer, T; Bunjes, D; Burchert, A; Busch, H; Cahn, JY; Caligiuri, MA; Chakraverty, R; Ciceri, F; Claus, R; Dengjel, J; Ditschkowski, M; Doostkam, S; Dörfel, D; Duquesne, S; Duyster, J; Ehlert, JE; Feger, D; Finke, J; Follo, M; Gerull, S; Gill, S; Haag, J; Hackanson, B; Häcker, G; Halbach, S; Halter, J; Hanke, K; Hemmati, P; Henden, AS; Herr, W; Hilgendorf, I; Hill, GR; Hochhaus, A; Holtick, U; Hu, Z; Ihorst, G; Illert, AL; Jilg, C; Kennedy, GA; Kim, DDH; Klaeger, S; Kobbe, G; Kondo, T; Kröger, N; Kuball, J; Kuchenbauer, F; Kuster, B; Labopin, M; Leiber, C; Lengerke, C; Lübbert, M; Mackensen, A; Magenau, J; Mathew, NR; McLornan, D; Meckel, S; Melchinger, W; Metzelder, SK; Mufti, G; Müller, AM; Müller, LP; Müller, TA; Nagler, A; Negrin, RS; Neubauer, A; O'Sullivan, D; Oran, B; Ordemann, R; Osswald, L; Pabst, T; Pearce, E; Pfeifer, D; Prinz, M; Reddy, P; Rezvani, K; Richardson, S; Rösler, W; Ruggiero, E; Rummelt, C; Sarma, A; Scheid, C; Schmid, C; Schmidts, A; Schmitt-Graeff, A; Schnell, J; Schroeder, T; Schultheiss, M; Shah, O; Sicre-de-Fontbrune, F; Socié, G; Spath, S; Spyridonidis, A; Stabla, K; Stölzel, F; Tanriver, Y; Taromi, S; Teshima, T; Thimme, R; Thomas, S; Tugues, S; Ullrich, E; Vago, L; van der Velden, W; von Bubnoff, N; Vuong, GL; Wagner, EM; Wäsch, R; Waterhouse, M; Weber, A; Weisdorf, D; Wilhelm, K; Wolf, D; Yan, KL; Zeiser, R | 1 |
| Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S | 1 |
| Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A | 1 |
| Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A | 1 |
| Chen, GH; Fu, CC; Gu, B; Han, Y; Ma, X; Miao, M; Qiu, HY; Shen, HJ; Sun, AN; Tang, XW; Wu, DP | 1 |
| Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y | 1 |
| Kallert, S; Mackensen, A; Meidenbauer, N; Rech, D; Rech, J; Roesler, W; Winkler, J | 1 |
| Childs, R; Lundqvist, A; Su, S; Yokoyama, H | 1 |
| Ausoni, G; Bayer, AJ; Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Mario, B; Metafuni, E; Sica, S; Sorà, F; Zini, G | 1 |
| Athar, U; Gentile, TC | 1 |
1 review(s) available for sorafenib and Graft vs Host Disease
| Article | Year |
|---|---|
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
5 trial(s) available for sorafenib and Graft vs Host Disease
| Article | Year |
|---|---|
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
Topics: Central Nervous System; Central Nervous System Neoplasms; Graft vs Host Disease; Humans; Leukemia; Recurrence; Retrospective Studies; Sorafenib | 2022 |
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.
Topics: Cytomegalovirus Infections; Epstein-Barr Virus Infections; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sorafenib | 2022 |
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Topics: Bronchiolitis Obliterans Syndrome; Disease Progression; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Sorafenib | 2023 |
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Topics: Adolescent; Adult; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2020 |
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutagenesis, Insertional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2014 |
11 other study(ies) available for sorafenib and Graft vs Host Disease
| Article | Year |
|---|---|
Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
Topics: fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Sorafenib | 2021 |
How Can We Distinguish Sorafenib-Associated Skin Rash From Skin Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation?
Topics: Exanthema; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Sorafenib; Transplantation, Homologous | 2021 |
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Topics: Activating Transcription Factor 4; Animals; CD8-Positive T-Lymphocytes; Cellular Reprogramming; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Interferon Regulatory Factor-7; Interleukin-15; Leukemia, Myeloid, Acute; Mice; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2018 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tandem Repeat Sequences | 2015 |
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib; Transplantation, Homologous | 2010 |
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Homologous | 2010 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2011 |